JY

The Joint Corp.

JYNTHealthcareNASDAQ

Medical Care Facilities

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$54.9M
+5.2% YoY
Net Income
$2.9M
+150.2% YoY
EBITDA
$808,241
-72.1% YoY
Free Cash Flow
$4.0M

Scan Results

Daily timeframe
2 recent days hidden. Fresh signals are a Premium featureUpgrade →
DateIndicatorDetails
Oct 20▲ MACD Positive CrossoverHistogram +0.0038, positive momentum
Oct 19▲ RSI OversoldRSI 18.9, below 30, stock may be oversold
About The Joint Corp.

The Joint Corp. operates and is a franchisor and operator of chiropractic clinics in the United States. Valued at $101.9M, JYNT is a micro-cap name in its sector. The company provides services under the franchise agreement, including training of franchisees and staff, site selection, construction/vendor management and ongoing operations support.

Where JYNT stands vs its 150-day and 200-day moving averages

As of the October 20, 2026 close, JYNT finished 14.47% below its 150-day moving average ($8.50) and 16.24% below its 200-day moving average ($8.68). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is JYNT overbought or oversold?

At the October 20, 2026 close, JYNT's RSI(14) was 35.1, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$101.9M
P/E (TTM)51.46
Fwd P/E10.83
EPS$0.14
Beta1.09
52W Change-14.2%
Dividend Yield0.00%
ROE10.6%
Analysis

The Joint Corp. holds $22.2M in cash against $2.0M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Annual free cash flow of $4.0M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 10.6%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 2.3% is on the lower side, which is common in asset-heavy industries. Revenue has been uneven over recent years, ranging from $80.0M to $54.9M.

The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The elevated P/E ratio means the stock is priced for significant future growth. If earnings disappoint, the price correction could be sharp. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing JYNT.

Links
More Healthcare stocks
Browse all stocks →
⚠Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms